Kymera Therapeutics Inc (KYMR) USD0.0001
Sell:$23.32Buy:$35.00
$0.30
(0.89%)
- This stock can be held in a
Stocks and Shares ISA$0.30
(0.89%)$0.30
(0.89%)Company Information
About this company
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.
Key people
Key facts
- EPICKYMR
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS5015751044
- Market cap$1.99bn
- Employees188
- Shares in issue64.94m
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.